Resultados de la búsqueda 271-280 of 14175 for Severe malaria

  1. Enfermedades alérgicas - Ensayos clínicos - Mayo Clinic

    These immune deficiency diseases are thought to be rare and include: Severe combined immunodeficiency (SCID), leukocyte adhesion deficiency (LAD), X-linked ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate immune profile of Acute Myeloid Leukemia (AML) patients receiving Venetoclax plus Azacitidine induction chemotherapy.

  3. Dermatología - Ensayos clínicos - Mayo Clinic

    The aims of this study are to determine the frequency, severity, and duration of symptoms of arthritis in patients with HS and compare them with those in ...

  4. Cirugía - Ensayos clínicos - Mayo Clinic

    This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  6. Mayo Clinic Physician Update - July 2022

    Page 1.

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate immune profile of Acute Myeloid Leukemia (AML) patients receiving Venetoclax plus Azacitidine induction chemotherapy. A ...

  8. Cirugía - Ensayos clínicos - Mayo Clinic

    A Study Of Vagus Nerve Stimulation (VNS) With Mobility Training For Gait Recovery After Chronic Ischemic Stroke. Rochester, Minn. The purpose of this study ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate immune profile of Acute Myeloid Leukemia (AML) patients receiving Venetoclax plus Azacitidine induction chemotherapy.